Stay updated with breaking news from Clinical Program Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected...
15.05.2023 - Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the ...
--Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting-- --Clinical...